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 1 
STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No. 
Recommendation 
Section, 
Paragraph 
No. 
Relevant text from manuscript 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term 
in the title or the abstract 
Title Acute cardiovascular events after herpes zoster: a self-controlled case 
series analysis in vaccinated and unvaccinated older residents of the 
United States  
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
Abstract Background 
Herpes zoster is common and can have serious consequences. 
Additionally, emerging data suggest an increased risk of acute 
cardiovascular events following herpes zoster. However, to our 
knowledge, existing association studies compare outcomes between 
individuals, and are therefore vulnerable to between-person 
confounding. In this study, we used a within-person study design to 
quantify any short-term increased risk of acute cardiovascular events 
(stroke and myocardial infarction) after zoster and to assess whether 
zoster vaccination modifies this association. 
Methods and Findings 
The self-controlled case series method was used to estimate rates of 
stroke and acute myocardial infarction in defined periods after herpes 
zoster compared to other time periods, within individuals. Participants 
were fully eligible Medicare beneficiaries aged ≥65 years with a herpes 
zoster diagnosis and either an ischemic stroke (n=42,954) or myocardial 
infarction (n=24,237) between 1st January 2006 and 31st December 
2011. Age-adjusted incidence ratios for stroke and myocardial infarction 
during pre-defined periods up to 12 months after zoster relative to 
unexposed time periods were calculated using conditional Poisson 
regression. We observed a marked increase in the rate of acute 
cardiovascular events in the first week after zoster: a 2.4-fold increased 
ischemic stroke rate (IR 2.37, 95% CI 2.17-2.59) and a 1.7-fold 
increased MI rate (IR 1.68, 95% CI 1.47-1.92), followed by a gradual 
 2 
resolution over six months. Zoster vaccination did not appear to modify 
the association with MI (interaction p value 0.44). We also found no 
evidence for a difference in the incidence ratios for ischemic stroke 
between vaccinated (IR 1.14, 95% CI 0.75-1.74) and unvaccinated (IR 
1.78, 95% CI 1.68-1.88) individuals during the first four weeks after 
zoster (interaction p value 0.28). The relatively few vaccinated 
individuals limited the study’s power to assess the role of vaccination.  
Conclusions 
Stroke and MI rates are transiently increased after exposure to herpes 
zoster. We found no evidence for a role for zoster vaccination in these 
associations. These findings enhance our understanding of the 
temporality and magnitude of the association between zoster and acute 
cardiovascular events. 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
Introduction, 
para 1-3 
Strong and increasing evidence supports a period of increased 
cardiovascular risk shortly after exposure to specific infections, with 
rates of myocardial infarction (MI) and stroke increased five and three-
fold respectively following acute respiratory infections.[1] The basis for 
increased cardiovascular events following acute infections is 
hypothesized to be due to endothelial dysfunction, characterized by 
atheromatous plaque rupture and the development of a prothrombotic 
environment.[2] As acute cardiovascular disease, specifically ischemic 
stroke and MI, are major causes of morbidity and mortality in the US 
and worldwide, understanding the basis for acute cardiovascular events 
and any potential for prevention becomes increasingly important.[3]  
Herpes zoster results from reactivation of dormant varicella zoster virus 
(VZV).  Herpes zoster is an important disease as it affects one million 
Americans per year and is frequently complicated by prolonged, severe 
disabling pain, post-herpetic neuralgia (PHN).[4,5] Zoster-associated 
morbidity has led to the introduction of a targeted vaccination program 
for individuals aged 60 years or greater in the US in 2006. The zoster 
 3 
vaccine has been shown to be effective in routine practice against 
incident zoster and PHN. Despite this, uptake of this vaccine has been 
disappointing (3.9%) following its introduction in the US, with 
important discrepancies in vaccine uptake by race and by income 
status.[6] 
Recent studies have proposed that the risk of stroke may be increased in 
the year following an acute episode of herpes zoster, possibly also 
mediated by VZV replication in arterial walls resulting in cerebral 
vasculopathy.[7] Most studies assessing the association between herpes 
zoster and stroke have been limited by residual confounding as 
comparisons were made between individuals who developed herpes 
zoster and those who did not, and these individuals have important 
differences in underlying vascular risk that are difficult to measure and 
account for. Our group used the self-controlled case series (SCCS) 
method, which eliminates between-person confounding, to demonstrate 
an increased risk of stroke in the first six months following herpes zoster 
in the UK population and that antiviral therapy might lessen this 
association.[8] One UK cohort study, which may be limited by residual 
confounding, also suggested a longer-term increased risk of stroke and 
MI up to 24 years following acute herpes zoster.[9] To our knowledge, 
no previous study has determined the risk of MI in the period 
immediately following herpes zoster or assessed the role of zoster 
vaccination in the association between zoster and acute cardiovascular 
events.  
Objectives 3 State specific objectives, including any prespecified 
hypotheses 
Introduction, 
para 4 
We used administrative claims data from older US Medicare 
beneficiaries to test the hypothesis of an increased risk of stroke and MI 
in periods shortly following acute episodes of herpes zoster and to assess 
whether zoster vaccination might modify this association. 
Methods  
Study design 4 Present key elements of study design early in the paper Methods: 
Study Design 
The SCCS method was used to estimate the rate of acute cardiovascular 
events (stroke and MI) in defined periods after herpes zoster compared 
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to other time periods, within individuals.[10] The SCCS approach 
overcomes the problem of between-person confounding inherent in other 
observational study designs by making within-person comparisons 
among individuals with zoster, whereby each case is his/her own 
control. 
Setting 5 Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-up, and 
data collection 
Methods: Data 
Source 
This study used Medicare administrative claims data (Research 
Identifiable Files including Medicare Provider Analysis and Review 
(MEDPAR) (inpatient hospital and skilled nursing facilities), Outpatient, 
Carrier (physician/supplier) and Prescription Drug claims) for the period 
1st January 2006 to 31st December 2011, obtained from the CMS. 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the 
sources and methods of selection of participants. Describe 
methods of follow-up 
Case-control study—Give the eligibility criteria, and the 
sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and 
controls 
Cross-sectional study—Give the eligibility criteria, and 
the sources and methods of selection of participants 
Methods: 
Participants 
The source population included all Medicare beneficiaries aged 65 years 
or older enrolled in Parts A (hospital insurance), B (supplemental 
medical insurance) and D (prescription drug coverage) who had both a 
zoster diagnosis and a Chronic Conditions Warehouse (CCW) flag for 
acute MI or stroke/transient ischemic attack (derived from the CMS’s 
own algorithms) during the study period. 
Participants were observed from the date they fulfilled the following 
criteria: i) 12 months continuous enrolment in Parts A and B, ii) eligible 
for Part D, and iii) not in a Health Maintenance Organization (HMO) 
(claims for beneficiaries enrolled in HMOs are not processed by CMS, 
hence their clinical data are incomplete). The 12 month minimum Part 
A/B enrolment criterion was applied to enable the study of incident 
rather than prevalent events. Observation was censored at the earliest of 
the date the participant died, joined a HMO, lost eligibility for part A, B 
or D, or the study period ended (31st December 2011). 
We identified each participant’s earliest recorded zoster episode and 
vascular event during the observation period and excluded individuals 
with evidence of vascular events or herpes zoster prior to the 
observation period. Diagnoses of incident events were extracted from 
Outpatient and Carrier (healthcare provider) files and from the primary 
diagnostic field in Inpatient files. Patients with only secondary inpatient 
diagnoses were excluded due to uncertainty of the timing of events that 
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were not the primary reason for admission to hospital and hence may 
have occurred at any time during hospitalization. For the stroke 
analyses, we additionally excluded individuals with: i) subarachnoid 
hemorrhage (SAH) or established risk factors for SAH including 
cerebral aneurysms in the circle of Willis or arteriovenous 
malformations at any time during enrolment, and ii) encephalitis 
diagnoses recorded up to 12 months after the stroke which may 
represent encephalitis initially misclassified as stroke.  
(b) Cohort study—For matched studies, give matching 
criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching 
criteria and the number of controls per case 
 N/A 
Variables 7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
Methods: 
Exposure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exposure 
We defined incident herpes zoster as the presence of a specific 
International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) diagnostic code 053x (where x indicates the 
4th/5th digits can take any value, excluding PHN codes 05312 and 05313) 
with an antiviral prescription in the seven days before or after diagnosis. 
The requirement for antiviral therapy has been shown to improve the 
positive predictive value of using zoster diagnosis codes to identify 
incident cases.[11] Herpes zoster ophthalmicus (HZO) was identified 
from ICD-9-CM codes 0532x recorded up to 12 months after the 
incident zoster code, or when zoster codes were nonspecific, either from 
acute eye infections or associated treatments within two weeks of the 
zoster diagnosis or from specific non-acute eye conditions associated 
with zoster, e.g. conjunctival scarring or episcleritis, recorded for the 
first time up to three months after zoster. HZO was analyzed separately 
as previous research suggested a markedly increased risk of stroke in 
this group.[12] In keeping with the primary zoster definition, an 
accompanying antiviral claim was also required for HZO. 
Herpes zoster vaccination status was ascertained from records of Current 
Procedural Terminology (CPT) code 90736 and National Drug Codes 
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Methods: 
Outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
for zoster vaccine purchase in the Part D drug files. Additionally, 
vaccine administration records up to seven days after purchase (CPT 
code 90471 or Healthcare Common Procedure Coding System 
(HCPCS) code G0377) were identified. We estimated the date of zoster 
vaccination as the earlier of the date of CPT code 90736 or date of 
administration. In the absence of a corresponding administration date 
and when no CPT code 90736 was recorded, the vaccine purchase date 
was used as a proxy (procedure/administration dates were considered 
better estimates of vaccination date than purchase dates). 
Outcomes 
We identified and classified acute cardiovascular events with specific 
ICD-9-CM codes for stroke (433x1, 434x1 (ischemic); 431, 4329 
(hemorrhagic) and 436 (nonspecific)) and MI (410x, excluding codes 
with 5th digit 2 indicating a subsequent episode of care). As our primary 
interest was in acute thrombotic cardiovascular events (ischemic stroke 
and MI), we excluded hemorrhagic strokes from the primary analysis. 
To do this, we created stroke episodes whereby successive stroke codes 
within 28 days of each other were assumed to correspond to the same 
episode to differentiate stroke subtypes (ischemic, hemorrhagic or 
unspecified). For episodes containing stroke codes of different types, we 
used the following hierarchy for classification: hemorrhagic codes took 
precedence (based on the assumption that hemorrhagic strokes are coded 
more accurately than ischemic strokes) and ischemic codes trumped 
nonspecific codes. Because hemorrhagic strokes could potentially result 
from arterial rupture or aneurysm following VZV vasculopathy, or from 
a transient spike in blood pressure (for example, in response to zoster-
associated pain), we undertook (in response to peer review) a secondary 
analysis of hemorrhagic strokes. To maintain an important assumption 
of the case series method – that recurrent outcome events within 
individuals are independent – we restricted all analyses to participants’ 
first stroke or MI in the observation period. 
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Methods: 
Comorbidities 
and 
demographics 
Comorbidities and demographics 
For descriptive purposes, pre-existing cardiovascular disease (CVD) 
(MI, stroke, transient ischemic attack, ischemic heart disease, heart 
failure or atrial fibrillation) and CVD risk factors (hypertension, 
hyperlipidemia, diabetes, chronic kidney disease or chronic obstructive 
pulmonary disease) were identified using CCW flags indicating the 
earliest occurrence of each condition. The number of unique 
prescriptions an individual received in the 12 months before their 
vascular event (as an indicator of overall poorer health) was determined 
by identifying all unique prescriptions and excluding duplicate 
records with the same product code or the same generic and brand 
names on the same date. Ethnicity was defined according to the Social 
Security Administration’s master beneficiary record (based on self-
report) and categorized into white, black, Asian, Hispanic and 
other/unknown. “State buy-in”, whereby the state pays Medicare 
premiums for low-income individuals, was used as a proxy for low 
income. Current age was derived from date of birth and included in all 
analyses as a time-varying covariate. 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and 
details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than 
one group 
Methods: 
Participants, 
para 2; 
 
 
 
Exposure, para 
2 
Diagnoses of incident events were extracted from Outpatient and Carrier 
(healthcare provider) files and from the primary diagnostic field in 
Inpatient files. Patients with only secondary inpatient diagnoses were 
excluded due to uncertainty of the timing of events that were not the 
primary reason for admission to hospital and hence may have occurred 
at any time during hospitalization. 
Herpes zoster vaccination status was ascertained from records of Current 
Procedural Terminology (CPT) code 90736 and National Drug Codes 
for zoster vaccine purchase in the Part D drug files. Additionally, 
vaccine administration records up to seven days after purchase (CPT 
code 90471 or Healthcare Common Procedure Coding System 
(HCPCS) code G0377) were identified. 
 8 
Bias 9 Describe any efforts to address potential sources of bias Methods: 
Study Design, 
para 1; 
 
Participants, 
para 2; 
 
 
Outcomes, 
para 1; 
 
 
Analysis, para 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The SCCS approach overcomes the problem of between-person 
confounding inherent in other observational study designs by making 
within-person comparisons among individuals with zoster, whereby each 
case is his/her own control. 
Patients with only secondary inpatient diagnoses were excluded due to 
uncertainty of the timing of events that were not the primary reason for 
admission to hospital and hence may have occurred at any time during 
hospitalization. 
To maintain an important assumption of the case series method – that 
recurrent outcome events within individuals are independent – we 
restricted all analyses to participants’ first stroke or MI in the 
observation period. 
Incidence ratios (IRs) for stroke and MI during pre-defined periods after 
exposure to zoster relative to unexposed time periods were calculated 
using conditional Poisson regression, adjusting for age in two-year 
bands. We defined a 12-month exposed period starting the day after 
zoster, subdivided into five risk windows: week 1, weeks 2-4, 5-12, 13-
26 and 27-52 post-zoster. When calculating the IR for any given risk 
window, the four remaining risk windows were still considered 
“exposed”. All other observation time made up the baseline (unexposed) 
period, with the exception of the day of zoster and the four weeks before 
zoster. The day of zoster was excluded as MI or stroke records on the 
same day as incident zoster may represent retrospective diagnoses. We 
excluded four weeks prior to zoster as vascular risk during this pre-
zoster period may be higher or lower than in other unexposed periods 
because the chance of developing and/or presenting with zoster shortly 
after a vascular event may differ from other time periods. Removing 
these periods from baseline was an attempt to avoid bias in the effect 
estimates that could have operated in either direction depending on the 
variation in vascular risk. 
 9 
Analysis, para 
3 
 
To allow for non-random censoring of observation due to death as a 
result of a vascular event (which may lead to bias if uncorrected), an 
extension to the standard SCCS method was used.[15] 
Study size 10 Explain how the study size was arrived at Methods: 
Participants, 
para 1 
The source population included all Medicare beneficiaries aged 65 years 
or older enrolled in Parts A (hospital insurance), B (supplemental 
medical insurance) and D (prescription drug coverage) who had both a 
zoster diagnosis and a Chronic Conditions Warehouse (CCW) flag for 
acute MI or stroke/transient ischemic attack (derived from the CMS’s 
own algorithms) during the study period. 
Quantitative variables 11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were 
chosen and why 
Methods: 
Comorbidities 
and 
demographics; 
Analysis, para 
1 
Current age was derived from date of birth and included in all analyses 
as a time-varying covariate.  
 
 
…adjusting for age in two-year bands. 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
Methods: 
Analysis, para 
1 
 
 
 
 
 
 
 
Analysis, para 
2 
 
 
 
 
Incidence ratios (IRs) for stroke and MI during pre-defined periods after 
exposure to zoster relative to unexposed time periods were calculated 
using conditional Poisson regression, adjusting for age in two-year 
bands. We defined a 12-month exposed period starting the day after 
zoster, subdivided into five risk windows: week 1, weeks 2-4, 5-12, 13-
26 and 27-52 post-zoster. When calculating the IR for any given risk 
window, the four remaining risk windows were still considered 
“exposed”. All other observation time made up the baseline (unexposed) 
period, with the exception of the day of zoster and the four weeks before 
zoster.  
The primary analysis assessed the association between zoster (all cases, 
irrespective of site) and ischemic stroke and MI separately. Additionally, 
the association between HZO and each outcome was assessed. A 
secondary analysis of hemorrhagic strokes (excluded from the primary 
analysis) was conducted to examine the association between zoster and 
this stroke sub-type. 
 10 
Analysis, para 
4 
Standard SCCS analyses were undertaken using STATA, version 13 
(StataCorp, College Station, Texas); modified analyses accounting for 
event-dependent censoring were performed in R, version 3.0.2. 
(b) Describe any methods used to examine subgroups and 
interactions 
Methods: 
Analysis, para 
2 
We undertook further analyses to explore whether vascular risk after 
zoster was different in those who received the zoster vaccine and those 
who did not. We defined vaccinated individuals as those who received 
the zoster vaccine before they developed zoster. To allow for effective 
immunization, these individuals were classified as vaccinated from 30 
days after receipt of the vaccine.[13] Hence for these stratified analyses, 
the adjusted start date for vaccinated individuals was from the later of 
this date and their original start date. “Unvaccinated” individuals 
comprised those who did not receive the zoster vaccine and additionally, 
those who were vaccinated after their incident zoster episode and whose 
observation was thus curtailed at vaccination. To allow for small 
numbers in the vaccinated strata, the first two risk windows post-zoster 
(week 1, weeks 2-4) were combined.  
(c) Explain how missing data were addressed  N/A 
(d) Cohort study—If applicable, explain how loss to 
follow-up was addressed 
Case-control study—If applicable, explain how matching 
of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy 
Methods: 
Participants, 
para 1 
Observation was censored at the earliest of the date the participant died, 
joined a HMO, lost eligibility for part A, B or D, or the study period 
ended (31st December 2011). 
(e) Describe any sensitivity analyses Methods: 
Analysis, para 
3 
To allow for non-random censoring of observation due to death as a 
result of a vascular event (which may lead to bias if uncorrected), an 
extension to the standard SCCS method was used.[15] In addition, the 
primary analysis was repeated excluding individuals who died or whose 
observation ended within 90 days after their vascular event (possibly 
indicating death).  
Results 
 11 
Participants 13* (a) Report numbers of individuals at each stage of study—
eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing 
follow-up, and analysed 
Results, para 1 The initial study population comprised 351,865 individuals, of whom 
42,954 zoster cases with incident ischemic stroke and 24,237 with acute 
MI fulfilled the eligibility criteria and were included in the primary 
analysis (Fig 2).  
(b) Give reasons for non-participation at each stage  See Fig 2. Identification of study participants  
(c) Consider use of a flow diagram  See Fig 2.  
Descriptive data 14* (a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on 
exposures and potential confounders 
Results, para 
1-2 
Characteristics of these individuals are presented in Table 1. The 
median age at zoster was 80 years (interquartile range (IQR) 74-86 
years) and median observation period was 5 years (IQR 4-5 years). The 
majority of participants were female (71% of zoster cases with stroke, 
64% of MIs) and white (88% of strokes, 90% of MIs); 5% were black, 
the remaining 6% were Asian (2%), Hispanic (2%) or of other/unknown 
ethnicity (2%). 16% of zoster cases had HZO, the remaining 84% had 
zoster of an unspecified site. 34% of cases were of low income and 90% 
had evidence of pre-existing cardiovascular disease (CVD) before 
zoster. 
A small minority of cases received the zoster vaccine before developing 
zoster (3% of cases with stroke, 2% of MIs), 6% received the vaccine 
after zoster and 91% were unvaccinated throughout the observation 
period. Characteristics of individuals included in the analyses stratified 
by zoster vaccination status are given in S1 Table in the Supplement. 
(b) Indicate number of participants with missing data for 
each variable of interest 
 See Table 1. Participant characteristics 
(c) Cohort study—Summarise follow-up time (eg, average 
and total amount) 
Results, para 1 …median observation period was 5 years (IQR 4-5 years). 
Outcome data 15* Cohort study—Report numbers of outcome events or 
summary measures over time 
Results, para 1 42,954 zoster cases with incident ischemic stroke and 24,237 with acute 
MI fulfilled the eligibility criteria and were included in the primary 
analysis.  
Note that this study is a self-controlled case series study using data from 
exposed cases only (individuals with both the exposure (herpes zoster) 
and the outcome (an acute vascular event). Hence all participants 
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experienced an outcome event and were exposed during the study 
period. 
Case-control study—Report numbers in each exposure 
category, or summary measures of exposure 
 N/A 
Cross-sectional study—Report numbers of outcome events 
or summary measures 
 N/A 
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision (eg, 
95% confidence interval). Make clear which confounders 
were adjusted for and why they were included 
Results, para 3 
& Table 2 
The rate of ischemic stroke was significantly increased up to three 
months after zoster (any site) compared to the baseline rate: the most 
marked increase, by 2.4-fold, was observed within the first week (IR 
2.37, 95% CI 2.17-2.59), reducing to 1.6-fold in weeks 2-4 (IR 1.55, 
95% CI 1.46-1.66), 1.2-fold in weeks 5-12 (IR 1.17, 95% CI 1.11-1.22), 
and resolving over the subsequent three months (weeks 13-26: IR 1.03, 
95% CI 0.99-1.07; weeks 27-52: IR 1.00, 95% CI 0.96-1.03). A similar 
though less marked association was observed for MI in the three months 
post-zoster, with a 68% increased MI rate in the first week (IR 1.68, 
95% CI 1.47-1.92) compared to baseline, and a similar pattern of 
resolution as for stroke (weeks 2-4: IR 1.25, 95% CI 1.14-1.37; weeks 5-
12: IR 1.07, 95% CI 1.00-1.14; weeks 13-26: IR 1.02, 95% CI 0.96-
1.07; weeks 27-52: IR 1.02, 95% CI 0.98-1.07)  
See Table 2. Primary analysis: Age-adjusted incidence ratios for stroke 
and myocardial infarction (MI) in risk periods after zoster.  
(b) Report category boundaries when continuous variables 
were categorized 
 See Table 2. 
(c) If relevant, consider translating estimates of relative 
risk into absolute risk for a meaningful time period 
 N/A 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Results, para 
4; 
Tables 3 & 4 
 
 
 
Analyses restricted to cases with HZO (n=6,971 with ischemic stroke, 3,946 
with MI) yielded comparable associations as the primary analysis (week 1 
post-HZO: stroke IR 2.73, 95% CI 2.22-3.35; MI IR 2.06, 95% CI 1.52-
2.79) that resolved over the same time period. 
See Table 3. Age-adjusted incidence ratios for stroke and myocardial 
infarction (MI) in risk periods after Herpes zoster ophthalmicus. 
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Results, para 
5 
 
 
 
 
 
 
 
 
 
 
 
Results, para 
6-7 
Stratifying by zoster vaccination status revealed no evidence for a reduced 
IR for ischemic stroke during the first four weeks after zoster among 
individuals who received the zoster vaccine (n=843) (IR 1.14, 95% CI 0.75-
1.74) compared to unvaccinated individuals (n=40,724) (IR 1.78, 95% CI 
1.68-1.88), (p value for interaction=0.28). The overall IR combining 
vaccinated and unvaccinated individuals for the same four-week post-zoster 
period was 1.76, 95% CI 1.67-1.86. There was no evidence that the IRs for 
MI after zoster varied according to zoster vaccination status (p=0.44): the IR 
in weeks 1-4 post-zoster was 1.36, 95% CI 0.78-2.39 in vaccinated 
individuals (n=400) and 1.37, 95% CI 1.26–1.48 in unvaccinated individuals 
(n=23,089), similar to the combined IR of 1.37, 95% CI 1.26-1.48 
See Table 4. Age-adjusted incidence ratios for vascular events in risk 
periods after zoster, stratified by vaccination status. 
The secondary analysis of hemorrhagic stroke (n=3109 cases) indicated a 
similar pattern of increase and resolution of risk as for ischemic/nonspecific 
stroke, though less pronounced and with reduced precision due to the 
relatively few cases. The largest increase in hemorrhagic stroke rate, by 1.6-
fold, was observed in weeks 2-4 post-zoster (IR 1.61, 95% CI 1.29-2.02), 
reducing to 1.3-fold in weeks 5-12 (IR 1.30, 95% CI 1.10-1.53) and 
resolving thereafter. 
Using the extension to the standard SCCS method to allow for non-random 
censoring of observation gave virtually identical results to those obtained in 
the primary analysis (S2 Table). Further sensitivity analyses excluding 
potentially fatal cases also gave similar findings (S3 Table). 
Discussion 
Key results 18 Summarise key results with reference to study objectives Discussion, 
para 1 
This study demonstrates that acute zoster is associated with transiently 
increased rates of stroke and MI. The most marked increase was observed 
during the first week following zoster with a 2.4-fold increased rate of 
ischemic stroke (IR 2.37, 95% CI 2.17-2.59) and a 1.7-fold increased MI 
rate (IR 1.68, 95% CI 1.47-1.92) followed by a gradual reduction over six 
months.  
 14 
Uptake of the zoster vaccine was low overall with only 9% of participants 
receiving the vaccine during the study period. We found no evidence for a 
reduction in the IRs for ischemic stroke or MI among vaccinees in the first 
four weeks after zoster.. 
Limitations 19 Discuss limitations of the study, taking into account sources 
of potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
Discussion, 
para 3-4 
Residual confounding is frequently an issue when using administrative data 
for research. However, as our analyses were within-person using the SCCS 
method, fixed confounders are inherently controlled for and we adjusted 
finely for increasing age over the observation period. Residual confounding 
by unmeasured time-varying factors is unlikely to produce the effect 
estimates observed; such factors would need to be associated with both the 
timing of zoster and the vascular event and be present in a sufficiently large 
proportion of study participants to introduce any material confounding. Such 
a factor could plausibly include major life events or stress.  
Medicare data are administrative data so misclassification of exposures and 
outcomes is possible. However, provided the exposure and outcome are 
ascertained independently, any such random misclassification in SCCS 
analyses would tend to bias findings towards the null.[22] We employed a 
strict definition of herpes zoster, requiring individuals to have received 
antiviral therapy to reduce misclassification from the possible use of “rule 
out” codes, whereby possible herpes zoster is coded as definite herpes 
zoster, as Medicare is an administrative data source.[11,23]  Use of this 
definition limited our ability to study the role of antiviral therapy in stroke 
and MI rates after zoster.  
Uptake of zoster vaccine was low (9%) among study participants (all of 
whom had zoster), with only 3% receiving the vaccine prior to developing 
zoster (the vaccine failures), and thus even with a very large data source 
there was limited power to assess whether vaccination modifies the 
association between zoster and acute cardiovascular events. 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Discussion, 
para 1 
Discussion, 
para 2 
The association we observed with MI is suggestive of a systemic association 
rather than one localized to the brain.  
We have previously demonstrated, using UK general practice data and the 
SCCS method, that the rate of stroke is increased in the first six months 
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Discussion, 
para 4 
 
 
 
 
 
 
Discussion, 
para 6 
following zoster, with the most marked increase being observed in the first 
four weeks following zoster and gradually reducing over time.[8]  We did 
not assess the association between zoster and MI in our previous study and 
the study period preceded the introduction of the zoster vaccine in the UK 
population. 
To our knowledge, all of the other studies that have assessed the risk of 
acute cardiovascular events following zoster have been limited by the 
potential for residual confounding due to the use of cohort designs and the 
inherent differences between individuals who develop zoster and those who 
do not develop zoster. Of these studies, two reported a 30% and a fourfold 
increased stroke risk in the year following zoster and HZO respectively in a 
Taiwanese cohort in an administrative database.[12,17] Details about the 
timing of stroke following zoster were not available from these studies. A 
Danish registry cohort study identified an increased stroke risk during the 
first year following zoster with the most pronounced increase being 
observed in the first two weeks following zoster, which is consistent with 
our observations in this current study.[18]  
The observed increased risk of stroke and MI following zoster is likely to be 
explained by multiple biological mechanisms. Our primary hypothesis was 
that inflammation may lead to arterial thrombosis on a background of 
atherosclerosis. A hemodynamic mechanism is also a possible basis for the 
increased risk of stroke following zoster. Acute elevation of blood 
pressure[21] relating to zoster-associated pain or stress, or alternatively 
VZV-induced vasculopathy with arterial rupture or aneurysm formation[7], 
could lead to increased risk of hemorrhagic strokes in particular. 
In conclusion, herpes zoster was associated with increased rates of both 
stroke and MI with a particularly marked increase in the first week 
following zoster, tailing off over a period of six months. The rapid increase 
in the rate of acute cardiovascular events followed by gradual resolution is 
supportive of a causative association. Zoster vaccination did not appear to 
modify the associations between zoster and ischemic stroke or MI; this 
finding requires further study due to low vaccination rates. 
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Generalisability 21 Discuss the generalisability (external validity) of the study 
results 
Discussion, 
para 3 
 
 
Discussion, 
para 5 
Our study is a large, population-based cohort of older individuals in the US. 
98% of the US population aged 65 years or greater are Medicare 
beneficiaries; hence the results of the study are reasonably generalizable to 
the older US population.  
… individuals who received antiviral therapy are likely to have had more 
severe zoster, hence study findings may be less applicable to individuals 
with mild zoster that would not warrant antiviral therapy. 
Other information  
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on 
which the present article is based 
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*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
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